Program
becotatug vedotin
Also written as “MRG003”, “MRG003+HX008” and “MRG003 + Pucotenlimab”.
Its studies are mostly in Squamous Cell Carcinoma of Head and Neck · Nasopharyngeal Carcinoma · Carcinoma, Non-Small-Cell Lung · Biliary Tract Neoplasms · Stomach Neoplasms, led by Lepu Biopharma.
Furthest: phase 3, since Feb 21, 202310 company-led studies, 5 open or runningNext primary completion: Aug 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Lepu Biopharma | 105 open or running | phase 3since Feb 21, 2023 | Apr 6, 2021 | Aug 2027phase 2 · NCT05688605 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 6, 2021First studies: 3 phase 2 studiesFirst studyNCT04838964, NCT04838548, NCT04868162
- Apr 29, 2021Phase 1 study in Advanced Solid TumorsNCT04868344 · 61 enrolled · China
- Nov 17, 2021Phase 2 study in RecurrenceNCT05126719 · 238 enrolled · China
- Jan 5, 2022Phase 2 study in Stomach NeoplasmsNCT05188209 · 6 enrolled · China
- Jan 6, 2023Phase 2 study in Advanced Solid TumorsNCT05688605 · 18 planned · China
- Feb 21, 2023Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT05751512 · 180 planned · China
- May 8, 2025Phase 3 study in RecurrenceNCT06976190 · 446 planned · China
- Apr 30, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07586124 · 80 planned · China
Ahead
- Aug 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT05688605
- Dec 2027Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07586124
- Dec 2027Primary completion: phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT05751512
- May 2029Primary completion: phase 3 study in RecurrenceNCT06976190
TargetBeta
EGFR →read by rule
“An antibody-drug conjugate (ADC) consisting of becotatug, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the epidermal growth factor receptor (EGFR) ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| befotertinibrule | Betta Pharmaceuticals | phase 3 | 6 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07586124Squamous Cell Carcinoma of Head and Neck · China | 2 | Recruiting | Dec 2027 | 80 |
| NCT06976190Recurrence · China | 3 | Recruiting | May 2029 | 446 |
| NCT05751512Squamous Cell Carcinoma of Head and Neck · China | 3 | Recruiting | Dec 2027 | 180 |
| NCT05688605Advanced Solid Tumors · China | 2 | Recruiting | Aug 2027 | 18 |
| NCT05188209Stomach Neoplasms · China | 2 | Terminated | Oct 12, 2022 | 6 |
| NCT05126719Recurrence · China | 2 | Active, not recruiting | Dec 30, 2024 | 238 |
| NCT04868344Advanced Solid Tumors · China | 1 | Completed | Mar 29, 2021 | 61 |
| NCT04868162Recurrence · China | 2 | Completed | Jul 26, 2024 | 70 |
| NCT04838548Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Mar 27, 2023 | 87 |
| NCT04838964Biliary Tract Neoplasms · China | 2 | Completed | Oct 20, 2022 | 15 |
How it is read
Names in the registry
- “MRG003”, 7 entries
- “MRG003+HX008”, 1 entry
- “MRG003 + Pucotenlimab”, 1 entry
- “Becotatug Vedotin for Injection”, 1 entry
Conditions, from the studies’ own filings
- Squamous Cell Carcinoma of Head and Neck, 3 studies
- Nasopharyngeal Carcinoma, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Biliary Tract Neoplasms, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.